Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 22;77:103894. doi: 10.1016/j.ebiom.2022.103894

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Authors

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Fig. 6. — AAT and IL-6 levels pre-and post (28 days) tocilizumab (8mg/kg) in ward level patients with SARS-CoV-2 infection with corresponding isoelectric focussing (IEF) gel.

a. Decrease in AAT plasma levels in ward level patients post tocilizumab (n = 10)

(P < 0.0001) (paired T test). b. Maintenance of elevated IL-6 plasma levels in the same cohort of ward level patients throughout their 28 day course (ns=0.099, paired T test). c. Increased IL-6/AAT ratio at day 28 post tocilizumab (P = 0.046, paired T test)) d. Glycosylation pattern pre- and post tocilizumab infusion as compared to ward level patients receiving standard of care (SOC), matched for a similar AAT level and inflammatory profile sampled at the same timepoints.